Gilead Sciences | GILD - Nettoeinkommen





Nettoeinkommen Veränderung Datum
AbbVie USD 3.61B 2.92B 2026-06
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
ALKERMES USD 501K 66.98M 2026-06
Alnylam Pharmaceuticals USD 164.49M 41.5M 2026-06
Amgen USD 2.38B 556M 2026-06
Biogen USD 97.5M 222M 2026-06
BioMarin Pharmaceutical USD 44.76M 60.76M 2026-06
Bristol-Myers Squibb USD 3.32B 640M 2026-06
Coherus Biosciences USD -37.64M 2.11M 2025-12
Eli Lilly USD 7.1B 301M 2026-06
Gilead Sciences USD -10.5B 12.52B 2026-06
GlaxoSmithKline GBP 435M 1.3B 2026-06
Glaxosmithkline GBP 1.74B 890.94M 2026-03
Incyte USD 585.6M 282.27M 2026-06
J&J USD 5.53B 299M 2026-06
Merck USD -1.34B 2.9B 2026-06
Moderna USD -1.34B 517M 2026-03
Neurocrine Biosciences USD 144.4M 53.5M 2026-06
Novartis USD 3.26B 108M 2026-06
Pfizer USD -248M 2.94B 2026-06
PTC Therapeutics USD -2.81M 132.16M 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 1.3B 569.7M 2026-06
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Sanofi EUR 343M 1.27B 2026-06
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
United Therapeutics USD 333M 58.1M 2026-06
Vertex Pharmaceuticals USD 1.1B 68.4M 2026-06